EDX Medical Group (AIM:EDX) has raised approximately £2.7m through a subscription for 19.38m new shares at 14p each.
The Cambridge-based diagnostics group develops digital testing products for early disease detection.
Each subscription share carries warrants over two further shares, exercisable at 3p between 20 July 2028 and 19 July 2029.
The net proceeds will fund expansion of EDX Medical's employee health screening service, which combines biomarker testing panels, general health checks and a bespoke follow-up diagnostic offering.
Discussions on definitive contracts with three significant UK employers, first flagged on 15 July, are progressing, with testing still expected to begin in the final quarter of 2026.
Two further large companies have since approached EDX Medical approximately the service, with talks ongoing.
Separately, the company confirmed that £860,000 of the £1.2m revenue it expected to record for the year ended 31 March has been deferred into the current financial year, following discussion with its auditors, as order processing extended beyond the year end.
"Investors in the Company have again demonstrated their confidence in the Company's strategy," said Professor Sir Chris Evans, OBE, founder of EDX Medical, adding that the fundraise supports expansion of the screening programme for "employers and employees" alike.
News Intelligence what this means for the company
EDX Medical raised £2.7m at 14p per share to fund expansion of its employee health screening service, with three major UK employer contracts progressing toward testing launch in Q4 2026 and two additional companies now in talks. The fundraise is backed by existing investor confidence and comes as the company defers £860k of expected revenue into the current year due to extended order processing—a timing issue rather than demand weakness, since initial fulfilment could generate more than £2 million in this financial year, plus repeat revenues in later years.
The raise funds a new revenue stream (corporate screening) that management projects could exceed £2m annually, but the deferral of £860k from the prior year signals execution risk in order processing. The warrant structure (2 further shares at 3p, exercisable 2028–2029) is dilutive if exercised, adding 38.76m shares to the 431.37m post-admission base—a 9% potential dilution—though only if the share price sustains above 3p in that window.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
